{"id":221341,"date":"2026-08-27T15:11:59","date_gmt":"2026-08-27T09:41:59","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=221341"},"modified":"2026-08-27T15:12:01","modified_gmt":"2026-08-27T09:42:01","slug":"low-debt-pharma-stocks-worth-watching-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/","title":{"rendered":"5 Low-Debt Pharma Stocks Worth Watching in 2026"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Sun Pharma D\/E 0.06 at Rs 1,912.40. Divis Labs D\/E 0.00 at Rs 9,076.00. Cipla D\/E 0.02 at Rs 1,414.30. Data as of 27 August 2026.<\/em><\/p>\n<div style=\"background: #F0F9FF; border-left: 4px solid #2E7D32; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0; color: #1f4e79; font-size: 14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin: 8px 0 0;\">The five low-debt pharma stocks worth watching in 2026 are Sun Pharmaceutical, Divis Laboratories, Cipla, Dr Reddys Laboratories and Alkem Laboratories, each carrying a debt to equity ratio of 0.20 or below. Indian pharma companies with strong export franchises and API businesses tend to generate steady cash flow, which reduces their need for borrowed capital. All five post positive return on equity and pay some dividend. A low debt to equity ratio limits refinancing risk, but regulatory approvals and pricing pressure remain separate factors to track.<\/p>\n<\/div>\n<p>India&#8217;s pharmaceutical sector includes several companies with unusually clean balance sheets, and low-debt pharma stocks are a common starting point for investors who want exposure to healthcare without high leverage risk. Sun Pharmaceutical, Divis Laboratories, Cipla, Dr Reddys Laboratories and Alkem Laboratories all carry a debt to equity ratio of 0.20 or below as of 27 August 2026, based on company filings.<\/p>\n<p>Large pharma companies with established export businesses and API manufacturing capacity typically generate strong operating cash flow, which reduces their reliance on external borrowing. This article covers the five names, their key numbers, and what a low leverage profile means for someone evaluating pharma stocks for a long term portfolio.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=lowdebt_pharma\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#What_Counts_as_a_Low-Debt_Pharma_Stock\" title=\"What Counts as a Low-Debt Pharma Stock?\">What Counts as a Low-Debt Pharma Stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#5_Low-Debt_Pharma_Stocks_Worth_Watching_in_2026\" title=\"5 Low-Debt Pharma Stocks Worth Watching in 2026\">5 Low-Debt Pharma Stocks Worth Watching in 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#1_Sun_Pharmaceutical\" title=\"1. Sun Pharmaceutical\">1. Sun Pharmaceutical<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#2_Divis_Laboratories\" title=\"2. Divis Laboratories\">2. Divis Laboratories<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#3_Cipla\" title=\"3. Cipla\">3. Cipla<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#4_Dr_Reddys_Laboratories\" title=\"4. Dr Reddys Laboratories\">4. Dr Reddys Laboratories<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#5_Alkem_Laboratories\" title=\"5. Alkem Laboratories\">5. Alkem Laboratories<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#Why_Low_Debt_Matters_for_Pharma_Investors\" title=\"Why Low Debt Matters for Pharma Investors\">Why Low Debt Matters for Pharma Investors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#Risks_to_Watch_Even_in_Low-Debt_Pharma_Stocks\" title=\"Risks to Watch Even in Low-Debt Pharma Stocks\">Risks to Watch Even in Low-Debt Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#How_to_Invest_in_These_Low-Debt_Pharma_Stocks\" title=\"How to Invest in These Low-Debt Pharma Stocks\">How to Invest in These Low-Debt Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#FAQs_on_Low-Debt_Pharma_Stocks\" title=\"FAQs on Low-Debt Pharma Stocks\">FAQs on Low-Debt Pharma Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#Which_are_the_top_low-debt_pharma_stocks_in_India_for_2026\" title=\"Which are the top low-debt pharma stocks in India for 2026?\">Which are the top low-debt pharma stocks in India for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#What_debt_to_equity_ratio_counts_as_low_debt_for_a_pharma_stock\" title=\"What debt to equity ratio counts as low debt for a pharma stock?\">What debt to equity ratio counts as low debt for a pharma stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#Is_Divis_Laboratories_a_debt-free_stock\" title=\"Is Divis Laboratories a debt-free stock?\">Is Divis Laboratories a debt-free stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#Are_low-debt_pharma_stocks_safer_than_other_pharma_stocks\" title=\"Are low-debt pharma stocks safer than other pharma stocks?\">Are low-debt pharma stocks safer than other pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#Do_low-debt_pharma_stocks_pay_dividends\" title=\"Do low-debt pharma stocks pay dividends?\">Do low-debt pharma stocks pay dividends?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#Which_low-debt_pharma_stock_has_the_lowest_debt_to_equity_ratio\" title=\"Which low-debt pharma stock has the lowest debt to equity ratio?\">Which low-debt pharma stock has the lowest debt to equity ratio?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/low-debt-pharma-stocks-worth-watching-2026\/#Should_I_buy_low-debt_pharma_stocks_only_for_their_low_debt\" title=\"Should I buy low-debt pharma stocks only for their low debt?\">Should I buy low-debt pharma stocks only for their low debt?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Counts_as_a_Low-Debt_Pharma_Stock\"><\/span><strong>What Counts as a Low-Debt Pharma Stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A low-debt pharma stock is one whose total borrowings are a small fraction of shareholder equity, typically shown as a debt to equity ratio under 0.25. Large pharma companies with diversified export markets and steady generics revenue often fall well below this level, since their cash conversion cycles are shorter than capital-intensive industries. A near zero ratio does not always mean zero borrowings, since lease liabilities for plants and offices count as debt under current accounting rules.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"5_Low-Debt_Pharma_Stocks_Worth_Watching_in_2026\"><\/span><strong>5 Low-Debt Pharma Stocks Worth Watching in 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below ranks five low-debt pharma stocks by market capitalisation, along with current market price, debt to equity ratio and 52 week trading range.<\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"8\">\n<thead>\n<tr>\n<th>Company<\/th>\n<th>NSE Ticker<\/th>\n<th>CMP (Rs)<\/th>\n<th>Debt to Equity<\/th>\n<th>Market Cap (Rs Cr)<\/th>\n<th>52W High (Rs)<\/th>\n<th>52W Low (Rs)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Sun Pharmaceutical<\/td>\n<td>SUNPHARMA<\/td>\n<td>1,912.40<\/td>\n<td>0.06<\/td>\n<td>4,56,114<\/td>\n<td>2,046.90<\/td>\n<td>1,548.00<\/td>\n<\/tr>\n<tr>\n<td>Divis Laboratories<\/td>\n<td>DIVISLAB<\/td>\n<td>9,076.00<\/td>\n<td>0.00<\/td>\n<td>2,39,321<\/td>\n<td>9,043.00<\/td>\n<td>5,636.50<\/td>\n<\/tr>\n<tr>\n<td>Cipla<\/td>\n<td>CIPLA<\/td>\n<td>1,414.30<\/td>\n<td>0.02<\/td>\n<td>1,13,778<\/td>\n<td>1,673.00<\/td>\n<td>1,165.70<\/td>\n<\/tr>\n<tr>\n<td>Dr Reddys Laboratories<\/td>\n<td>DRREDDY<\/td>\n<td>1,171.40<\/td>\n<td>0.20<\/td>\n<td>99,026<\/td>\n<td>1,414.90<\/td>\n<td>1,101.00<\/td>\n<\/tr>\n<tr>\n<td>Alkem Laboratories<\/td>\n<td>ALKEM<\/td>\n<td>5,328.00<\/td>\n<td>0.15<\/td>\n<td>63,850<\/td>\n<td>5,933.50<\/td>\n<td>5,075.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"1_Sun_Pharmaceutical\"><\/span><strong>1. Sun Pharmaceutical<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sun Pharmaceutical is the largest of the low-debt pharma stocks on this list, with a market capitalisation of Rs 4,56,114 crore and a debt to equity ratio of 0.06. The stock trades at Rs 1,912.40, below its 52 week high of Rs 2,046.90, supported by growth in its specialty and branded formulations business. Return on equity stands at 13.74 percent and the dividend yield is 0.84 percent. Sun Pharma&#8217;s diversified revenue base across India, the US and emerging markets has helped it fund expansion largely from internal cash flow.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Divis_Laboratories\"><\/span><strong>2. Divis Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Divis Laboratories reports a debt to equity ratio of 0.00, making it the cleanest balance sheet in this list, and the stock recently touched a fresh 52 week high near Rs 9,076.00 intraday. Market capitalisation stands at Rs 2,39,321 crore. As a leading API and custom synthesis manufacturer for global pharma clients, Divis Laboratories has funded its capacity expansion almost entirely from operating cash flow. Return on equity is 15.32 percent, and the dividend yield of 0.33 percent is modest since the company reinvests heavily in new manufacturing capacity.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Cipla\"><\/span><strong>3. Cipla<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Cipla carries a debt to equity ratio of 0.02 and trades at Rs 1,414.30, with a market cap of Rs 1,13,778 crore. Its 52 week range runs from Rs 1,165.70 to Rs 1,673.00. The company&#8217;s respiratory and generics portfolio across India, South Africa and the US supports a return on equity of 11.27 percent and a dividend yield of 0.92 percent. Cipla&#8217;s low leverage has given it flexibility to invest in complex generics and biosimilars without added interest burden.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live debt to equity data<\/strong><\/a><\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Dr_Reddys_Laboratories\"><\/span><strong>4. Dr Reddys Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr Reddys Laboratories has a debt to equity ratio of 0.20, the highest among the five names on this list but still low by industry standards, and the stock trades at Rs 1,171.40 with a market capitalisation of Rs 99,026 crore. The 52 week range runs from Rs 1,101.00 to Rs 1,414.90. Return on equity stands at 11.07 percent and the dividend yield is 0.67 percent. Dr Reddys runs a global generics and biosimilars business spanning the US, Russia and India.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Alkem_Laboratories\"><\/span><strong>5. Alkem Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Alkem Laboratories rounds out the list with a debt to equity ratio of 0.15 and a current market price of Rs 5,328.00. Market capitalisation stands at Rs 63,850 crore, with a 52 week range of Rs 5,075.00 to Rs 5,933.50. The company&#8217;s domestic-focused branded generics business supports a return on equity of 16.66 percent and a dividend yield of 0.99 percent, among the higher payouts on this list.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track these low-debt pharma stocks on the go.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Low_Debt_Matters_for_Pharma_Investors\"><\/span><strong>Why Low Debt Matters for Pharma Investors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Lower Interest Cost Risk:<\/strong> A company with little borrowing is largely insulated from rising interest rates, since it has few loans whose cost can climb during a tightening cycle.<\/p>\n<p><strong>Room to Absorb Regulatory Costs:<\/strong> Pharma companies periodically face compliance and remediation costs at manufacturing plants, and a low-debt balance sheet gives more room to absorb these without added financial strain.<\/p>\n<p><strong>Higher Dividend and Buyback Capacity:<\/strong> Cash that would otherwise service debt is available for dividends or buybacks, which is one reason several names on this list maintain steady payouts.<\/p>\n<p><strong>Flexibility to Fund R&amp;D:<\/strong> A clean balance sheet gives management room to fund research, clinical trials or capacity expansion from internal accruals rather than fresh loans.<\/p>\n<p><strong>Resilience to Pricing Pressure:<\/strong> Companies without debt obligations face less pressure to cut costs sharply when generic pricing in the US or other markets comes under pressure.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Watch_Even_in_Low-Debt_Pharma_Stocks\"><\/span><strong>Risks to Watch Even in Low-Debt Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Valuation Risk:<\/strong> A low debt to equity ratio does not protect a stock from being expensive. Divis Laboratories, for instance, trades at a price to earnings ratio of 81.82, well above the sector average.<\/p>\n<p><strong>USFDA and Regulatory Action:<\/strong> Manufacturing plant inspections and warning letters from the USFDA or other regulators can disrupt supply and dent revenue regardless of balance sheet strength.<\/p>\n<p><strong>US Generic Pricing Pressure:<\/strong> Continued price erosion in the US generics market can compress margins for companies with significant US exposure.<\/p>\n<p><strong>Currency Fluctuation:<\/strong> Since a large share of revenue for these companies is earned in US dollars or other foreign currencies, rupee movements can affect reported earnings.<\/p>\n<p><strong>Patent Litigation and Competition:<\/strong> Complex generic launches and patent challenges can affect the timing and size of revenue from key products.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_These_Low-Debt_Pharma_Stocks\"><\/span><strong>How to Invest in These Low-Debt Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start by comparing the debt to equity ratio, price to earnings ratio and dividend yield of each stock against its own five year average, rather than looking at the number in isolation.<\/p>\n<p>A live fundamentals screener can help with this comparison, since debt to equity, PE and dividend yield figures move every quarter and a static snapshot goes stale quickly.<\/p>\n<p>Next, check recent commentary on USFDA plant inspections, new product approvals and pricing trends in key export markets, since these factors move pharma stocks more than balance sheet strength alone.<\/p>\n<p>Decide on a position size based on your existing exposure to the pharma sector, since these five names already sit in most healthcare-focused mutual funds and may overlap with existing holdings.<\/p>\n<p>Finally, place the order through a SEBI registered broker or investment platform, and set a review date, such as the next quarterly results, rather than relying on the current debt to equity figure indefinitely.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sun Pharmaceutical, Divis Laboratories, Cipla, Dr Reddys Laboratories and Alkem Laboratories currently stand out as low-debt pharma stocks with debt to equity ratios between 0.00 and 0.20, positive return on equity, and export-led business models. A clean balance sheet lowers one category of risk, but regulatory outcomes and pricing pressure still need to be assessed stock by stock. Consult a SEBI registered advisor before making any investment decision, and treat the figures in this article as a starting point for further research rather than a final recommendation.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Low-Debt_Pharma_Stocks\"><\/span><strong>FAQs on Low-Debt Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_top_low-debt_pharma_stocks_in_India_for_2026\"><\/span><strong>Which are the top low-debt pharma stocks in India for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sun Pharmaceutical, Divis Laboratories, Cipla, Dr Reddys Laboratories and Alkem Laboratories are among the top low-debt pharma stocks in India for 2026, each with a debt to equity ratio of 0.20 or below as of 27 August 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_debt_to_equity_ratio_counts_as_low_debt_for_a_pharma_stock\"><\/span><strong>What debt to equity ratio counts as low debt for a pharma stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> A debt to equity ratio under 0.25 is generally treated as low debt for pharma companies, since export-led manufacturers with steady cash flow rarely need significant borrowing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Divis_Laboratories_a_debt-free_stock\"><\/span><strong>Is Divis Laboratories a debt-free stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divis Laboratories reports a debt to equity ratio of 0.00, the lowest among large listed pharma companies, along with a return on equity of 15.32 percent.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Are_low-debt_pharma_stocks_safer_than_other_pharma_stocks\"><\/span><strong>Are low-debt pharma stocks safer than other pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Low-debt pharma stocks carry lower interest rate and refinancing risk than leveraged companies, but they are not immune to USFDA action, pricing pressure or currency fluctuation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Do_low-debt_pharma_stocks_pay_dividends\"><\/span><strong>Do low-debt pharma stocks pay dividends?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Most low-debt pharma stocks on this list pay some dividend, with Alkem Laboratories at 0.99 percent yield and Sun Pharmaceutical at 0.84 percent, though payouts are generally modest compared to FMCG.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_low-debt_pharma_stock_has_the_lowest_debt_to_equity_ratio\"><\/span><strong>Which low-debt pharma stock has the lowest debt to equity ratio?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divis Laboratories has the lowest debt to equity ratio in this list at 0.00, followed by Cipla at 0.02.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_buy_low-debt_pharma_stocks_only_for_their_low_debt\"><\/span><strong>Should I buy low-debt pharma stocks only for their low debt?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Low debt should be one factor among several, alongside regulatory track record, export mix and return on equity, when deciding whether to buy any of these low-debt pharma stocks.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sun Pharma, Divis Labs, Cipla, Dr Reddys and Alkem Laboratories all carry a debt to equity ratio of 0.20 or below. See CMP, ROE and 52 week range for each.<\/p>\n","protected":false},"author":35,"featured_media":221340,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3802],"class_list":["post-221341","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["221340"],"_edit_lock":["1787823724:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["24"],"rank_math_seo_score":["79"],"rank_math_title":["Low-Debt Pharma Stocks 2026: Top 5 Picks by Market Cap"],"rank_math_description":["5 low-debt pharmaceutical stocks in India for 2026 ranked by market cap, with debt to equity, CMP, 52 week range and return on equity for each name."],"rank_math_focus_keyword":["low-debt pharma stocks"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["40293"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/low-debt-pharma-stocks-worth-watching-2026.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/221341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=221341"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/221341\/revisions"}],"predecessor-version":[{"id":221371,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/221341\/revisions\/221371"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/221340"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=221341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=221341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=221341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}